The global biopharmaceutical and medical technology (MedTech) sectors have entered a period of structural dealmaking transformation. Historically, large scale mergers and acquisitions (M&A) served as the primary instrument for multinational pharmaceutical corporations (MNCs) seeking to replenish depleted R&D pipelines, acquire proprietary drug discovery platforms and secure top-line growth. However, the economic rationale underpinning transformative M&A has been reshaped by a